Literature DB >> 28628428

ERAAs for menopause treatment: Welcome the 'designer estrogens'.

Heather D Hirsch1,2, Elim Shih3, Holly L Thacker4,5.   

Abstract

Estrogen receptor agonist-antagonists (ERAAs) selectively inhibit or stimulate estrogen-like action in targeted tissues. This review summarizes how ERAAs can be used in combination with an estrogen or alone to treat menopausal symptoms (vasomotor symptoms, genitourinary syndrome of menopause), breast cancer or the risk of breast cancer, osteopenia, osteoporosis, and other female midlife concerns.
Copyright © 2017 Cleveland Clinic.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28628428     DOI： 10.3949/ccjm.84a.15140

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN： 0891-1150            Impact factor:   2.321


  3 in total

1.  Medroxyprogesterone Acetate Prevention of Cervical Cancer through Progesterone Receptor in a Human Papillomavirus Transgenic Mouse Model.

Authors:  Seunghan Baik; Fabiola F Mehta; Sang-Hyuk Chung
Journal:  Am J Pathol       Date:  2019-11-12       Impact factor: 4.307

Review 2.  Therapeutic Perspectives of 8-Prenylnaringenin, a Potent Phytoestrogen from Hops.

Authors:  Kateřina Štulíková; Marcel Karabín; Jakub Nešpor; Pavel Dostálek
Journal:  Molecules       Date:  2018-03-15       Impact factor: 4.411

3.  SIRT1 and Gender Differences in Atherosclerotic Cardiovascular Disease.

Authors:  Michio Shimabukuro
Journal:  J Atheroscler Thromb       Date:  2019-10-30       Impact factor: 4.928
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.